Bridging Epigenomics and Tumor Immunometabolism: Molecular Mechanisms and Therapeutic Implications

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2025 Mar 8

PMID 40057791

Authors

Xiaowen Xie

Weici Liu

Zhiyuan Yuan

Hanqing Chen

Wenjun Mao

Affiliations

Soon will be listed here.

Abstract

Epigenomic modifications-such as DNA methylation, histone acetylation, and histone methylation-and their implications in tumorigenesis, progression, and treatment have emerged as a pivotal field in cancer research. Tumors undergo metabolic reprogramming to sustain proliferation and metastasis in nutrient-deficient conditions, while suppressing anti-tumor immunity in the tumor microenvironment (TME). Concurrently, immune cells within the immunosuppressive TME undergo metabolic adaptations, leading to alterations in their immune function. The complicated interplay between metabolites and epigenomic modulation has spotlighted the significance of epigenomic regulation in tumor immunometabolism. In this review, characteristics of the epigenomic modification associated with tumors are systematically summarized alongside with their regulatory roles in tumor metabolic reprogramming and immunometabolism. Classical and emerging approaches are delineated to broaden the boundaries of research on the crosstalk research on the crosstalk between tumor immunometabolism and epigenomics. Furthermore, we discuss potential therapeutic strategies that target tumor immunometabolism to modulate epigenomic modifications, highlighting the burgeoning synergy between metabolic therapies and immunotherapy as a promising avenue for cancer treatment.

References

Sun Z, Zhang L, Liu L . Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy. Biomed Pharmacother. 2023; 167:115574. DOI: 10.1016/j.biopha.2023.115574. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Yi X, Zhu Q, Wu X, Tan T, Jiang X . Histone Methylation and Oxidative Stress in Cardiovascular Diseases. Oxid Med Cell Longev. 2022; 2022:6023710. PMC: 8942669. DOI: 10.1155/2022/6023710. View

Hochrein S, Wu H, Eckstein M, Arrigoni L, Herman J, Schumacher F . The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. Cell Metab. 2022; 34(4):516-532.e11. PMC: 9019065. DOI: 10.1016/j.cmet.2022.02.015. View

Wan J, Liu H, Chu J, Zhang H . Functions and mechanisms of lysine crotonylation. J Cell Mol Med. 2019; 23(11):7163-7169. PMC: 6815811. DOI: 10.1111/jcmm.14650. View

Chen Q, Yang B, Liu X, Zhang X, Zhang L, Liu T . Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022; 12(11):4935-4948. PMC: 9274749. DOI: 10.7150/thno.73223. View

Huang W, Li H, Yu Q, Xiao W, Wang D . LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res. 2022; 41(1):100. PMC: 8922926. DOI: 10.1186/s13046-022-02319-z. View

Panatta E, Butera A, Mammarella E, Pitolli C, Mauriello A, Leist M . Metabolic regulation by p53 prevents R-loop-associated genomic instability. Cell Rep. 2022; 41(5):111568. DOI: 10.1016/j.celrep.2022.111568. View

Tian Y, Ma J, Wang H, Yi X, Wang H, Zhang H . BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressions. Cell Mol Life Sci. 2023; 80(11):315. PMC: 11073144. DOI: 10.1007/s00018-023-04965-8. View

10.

Nachef M, Ali A, Almutairi S, Lee S . Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. Front Immunol. 2021; 12:624324. PMC: 8089370. DOI: 10.3389/fimmu.2021.624324. View

11.

Sinha S, Satpathy A, Zhou W, Ji H, Stratton J, Jaffer A . Profiling Chromatin Accessibility at Single-cell Resolution. Genomics Proteomics Bioinformatics. 2021; 19(2):172-190. PMC: 8602754. DOI: 10.1016/j.gpb.2020.06.010. View

12.

De Sa Fernandes C, Novoszel P, Gastaldi T, Krauss D, Lang M, Rica R . The histone deacetylase HDAC1 controls dendritic cell development and anti-tumor immunity. Cell Rep. 2024; 43(6):114308. DOI: 10.1016/j.celrep.2024.114308. View

13.

Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y . HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition. Cancer Res. 2019; 79(14):3676-3688. PMC: 6679938. DOI: 10.1158/0008-5472.CAN-18-3767. View

14.

Keating S, El-Osta A . Metaboloepigenetics in cancer, immunity, and cardiovascular disease. Cardiovasc Res. 2022; 119(2):357-370. PMC: 10064843. DOI: 10.1093/cvr/cvac058. View

15.

Chung C, Sweha S, Pratt D, Tamrazi B, Panwalkar P, Banda A . Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell. 2020; 38(3):334-349.e9. PMC: 7494613. DOI: 10.1016/j.ccell.2020.07.008. View

16.

Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J . Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Eur Urol. 2018; 75(5):752-763. DOI: 10.1016/j.eururo.2018.09.030. View

17.

Nishikawa H, Koyama S . Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021; 9(7). PMC: 8327843. DOI: 10.1136/jitc-2021-002591. View

18.

Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M . ATP citrate lyase: A central metabolic enzyme in cancer. Cancer Lett. 2019; 471:125-134. DOI: 10.1016/j.canlet.2019.12.010. View

19.

Ringel A, Drijvers J, Baker G, Catozzi A, Garcia-Canaveras J, Gassaway B . Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020; 183(7):1848-1866.e26. PMC: 8064125. DOI: 10.1016/j.cell.2020.11.009. View

20.

Buglakova E, Ekelof M, Schwaiger-Haber M, Schlicker L, Molenaar M, Shahraz M . Spatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer. Nat Metab. 2024; 6(9):1695-1711. PMC: 11422168. DOI: 10.1038/s42255-024-01118-4. View